Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Esophageal cancer
Stage/Subtype:  stage III esophageal cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 27 for your search:
Start Over
Proton Beam Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients with Esophageal Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 2011-1036, NCI-2012-00078, NCT01512589
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CMEK162X2109, NCI-2012-00874, 2011-002578-21, NCT01449058
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CRAB CTC 11-001, NCI-2014-02260, CAR-IST-553, NCI-2013-02243, NCT01941316
HuMax®-TF-ADC Safety Study in Patients With Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GEN701, NCI-2014-01166, NCT02001623
Pembrolizumab, Combination Chemotherapy, and Celecoxib in Treating Patients with Advanced Colorectal, Appendix, Gastroesophageal, Pancreatic, or Biliary Tract Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: HCI76239, NCI-2015-00123, 3475-085, 76239, MK-3475 GI, NCT02268825
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CPDR001X2101, NCI-2015-00577, 2014-003929-17, NCT02404441
Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLAG525X2101C, NCI-2015-00966, NCT02460224
Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CP-MGAH22-05, NCI-2016-00290, NCT02689284
Docetaxel, Cisplatin, and Fluorouracil in Treating Patients with Gastric or Gastroesophageal Junction Cancer That is Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 06-103, NCI-2015-01798, NCT00515411
Plicamycin in Treating Patients with Malignancies Involving the Lungs, Esophagus, or Pleura That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-C-0151, NCI-2013-01534, 120151, P12961, NCT01624090
Combination Chemotherapy in Treating Patients with Advanced Stomach, Gastroesophageal, or Esophageal Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 201309035, NCI-2013-01783, NCT01928290
MatriStem Surgical Matrix PSM in Reducing Complications in Patients with Stomach or Esophageal Cancer Undergoing Surgery
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 13-178, NCI-2013-02006, NCT01970306
Regorafenib in Treating Patients with Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RU021212I, NCI-2015-01699, NCI-2014-01962, NCT02234180
Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 3475-180, NCI-2015-02092, 163188, 2015-002427-26, NCT02559687
Capecitabine in Treating Patients with Metastatic Breast Cancer or Advanced/Metastatic Gastrointestinal Cancers
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2015-IIT-X7-7, NCI-2016-00409, STUDY00002962, NCT02595320
Autologous Cytotoxic T Lymphocytes in Treating Patients With Advanced HER2- Positive Malignancy
Status: Active
Phase: Phase I
Type: Treatment
Age: 3 and over
Trial IDs: H-24486, NCI-2012-00777, NCT00889954
Veliparib, Paclitaxel, and Carboplatin in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 10-115, NCI-2011-02500, CDR0000700997, 8808, NCT01366144
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B2151002, NCI-2013-01814, 2013-001390-24, NCT01920061
Heated Cisplatin following Surgery in Treating Younger Patients with Primary or Metastatic Pleural Malignancies
Status: Active
Phase: Phase I
Type: Treatment
Age: 3 to 21
Trial IDs: 2012-0657, NCI-2014-01101, NCI-2014-00510, NCT01998529
A Study of DKN-01 in Combination With Paclitaxel
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 30 and over
Trial IDs: DEK-Dkk1-P102, NCI-2014-00704, DKN-01, LY2812176, NCT02013154
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BBI608-246, NCI-2015-00892, NCT02024607
Sonidegib and Everolimus in Treating Patients with Advanced Gastroesophageal Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0838, NCI-2014-01455, NCT02138929
Alisertib and Combination Chemotherapy in Treating Patients with Gastrointestinal Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: VICC GI1536, NCI-2014-02475, 9824, NCT02319018
Start Over